Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus
NCT ID: NCT01095991
Last Updated: 2010-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
12 participants
INTERVENTIONAL
2010-03-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus
NCT00551590
Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
NCT03359590
Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy
NCT01859793
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
NCT01937598
Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
NCT00337610
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
AZD1656, day 1-5, AZD1656 + Sitagliptin day 6-10, Sitagliptin day 11-15.
AZD1656
Oral tablet bd,
Sitagliptin
Oral tablet od
2
Sitagliptin day 1-5, AZD1656 + Sitagliptin day 6-10, AZD1656 day 11-15.
AZD1656
Oral tablet bd,
Sitagliptin
Oral tablet od
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD1656
Oral tablet bd,
Sitagliptin
Oral tablet od
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index between ≥19 and ≤42 kg/m2.
Exclusion Criteria
* Clinically significant illness or clinically relevant trauma.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stanko Skrtic
Role: STUDY_DIRECTOR
AstraZeneca Molndal Sweden
Christoph Kapitza
Role: PRINCIPAL_INVESTIGATOR
Profil Institut für Stoffwechselforschung GmbH
Mirjana Kujacic
Role: STUDY_DIRECTOR
AstraZeneca Molndal Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Neuss, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1020C00032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.